A pathophysiological role for heparin-binding EGF-like growth factor in myocardial injury
The biological function of tissue trophic factors is of obvious importance in development. What has become overwhelmingly clear is that secreted factors have enormous influence on the ability of tissues to recover from injury. A case in point is the recovery of the myocardium from infarction. Insulin-like growth factor (IGF), hepatocyte growth factor (HGF), and heparin-binding EGF-like growth factor (HB-EGF) all have emerged as cardiogeneic and cardiohypertrophic growth factors. For instance, HB-EGF-null mice develop severe heart failure after birth. HB-EGF is synthesized as a type-I transmembrane protein (proHB-EGF); this form of the protein may be mitogenic or growth inhibitory, depending upon the cell type. Membrane-bound proHB-EGF is cleaved by a specific metalloproteinase, releasing soluble HB-EGF. The latter is a potent mitogen for vascular smooth muscle cells, fibroblasts, and other cell types. While the beneficial effects of IGF and HGF have been well demonstrated in injured hearts, it is unclear whether the natural upregulation of HB-EGF expression that occurs following cardiac injury benefits or impairs the recovery of the heart. In this issue, Ushikoski et al 1 (p. 862) utilized adenoviral HB-EGF gene transduction in vitro and in vivo to demonstrate that overexpression of HB-EGF had no cytoprotective effect on Fas-induced apoptosis or oxidative stress injury in primary cultured mouse cardiomyocytes. Absent injury, HB-EGF was capable of inducing hypertrophy of cardiomyocytes and proliferation of cardiac fibroblasts. In vivo, local overexpression of HB-EGF in the border areas of a myocardial infarction in rabbits did not improve cardiac function or promote angiogenesis. These studies were performed utilizing an adenoviral vector, which gave greater temporal control of HB-EGF expression than would be possible with a murine transgenic overexpression approach. In this rabbit model, HB-EGF increased levels of apoptosis and fibrosis in the infarcted region following reperfusion, and increased the numbers of myofibroblasts and macrophages. Myocardial hypertrophy only occurred elsewhere in the left ventricle. Hence, overexpressed HB-EGF in the infarcted region did not result in a beneficial outcome, but rather exacerbated the remodeling process through the mitogenic activation of fibroblasts into myofibroblasts, deposition of fibrous tissue, and the recruitment of inflammatory cells. Moreover, HB-EGF was not cytoprotective, as it did not inhibit apoptosis of cardiomyocytes under conditions of oxidative stress as would occur in the postinfarction state. Myocardial remodeling following myocardial infarction may therefore be guided down a pathogenic pathway of fibrosis and aberrant remodeling as a result of HB-EGF expression. This novel observation has significant bearing in the understanding and potential therapy of heart injury, including recovery from myocardial infarction. 
Progress in understanding colitis: a role for epithelial CD98
CD98 is a cell surface glycoprotein composed of covalently linked heavy and light chains. It was originally described as a lymphocyte activation antigen, but in polarized epithelia CD98 is localized to the basolateral domain where it functions as an amino-acid transporter and regulator of b1 integrin function. Epithelial CD98 can also interact with epithelial intercellular adhesion molecule I (ICAM-1). Together with a variety of functional data these observations raise the possibility that adhesion and amino-acid transport activity may be coordinately regulated by interactions between CD98, ICAM-1, and b1 integrins. In this issue, Kucharzik et al 1 (p. 932) extend previous reports of increased CD98 expression on lymphocytes and epithelia in response to TH1 cytokines. Since epithelial CD98 regulates b1 integrins, which may be involved in inflammatory disease, the authors hypothesized that epithelial CD98 might also be involved in intestinal disease. They first showed that epithelial CD98 was upregulated in intestinal epithelial cells exposed to interferon-g in vitro. They then demonstrated similar upregulation in vivo following DSS exposure, a standard murine model of colitis. This increased CD98 expression did not occur in interferon-g knockout mice, demonstrating the critical in vivo role of interferon-g in regulation of CD98 expression.
Further studies showed that administration of an activating anti-CD98 monoclonal antibody worsened colitis in DSS-treated mice, demonstrating a functional role for CD98 in colitis. These two studies support a basic mechanism by which upregulation of FLIP promotes improved survival and chemoresistance in two distinctly different forms of neoplasia. It follows that researchers developing targeted antiapoptotic cancer therapies should consider the 'FLIP side' in future laboratory investigations. 
Malignant transformation of thymoma in the setting of HTLV-I
The human T lymphocyte virus type-I (HTLV-I) is causally implicated in adult T-cell leukemia/lymphoma and is associated with several autoimmune and inflammatory disorders. Tax, encoded by the pX gene of HTLV-I, is a protein that modulates the function of growth factors, transcription factors and cellcycle-related molecules such as p53 and p16ink4a that are crucial for cell survival and proliferation. For this reason, the pX gene is thought to play a major role in HTLV-1 tumorigenesis. Very few animal models are available to study tumorigenesis in thymomas. Kikuchi et al 1 reported earlier that transgenic rats carrying the pX gene under the control of a rat lymphocyte-specific protein tyrosine kinase type-I promoter (lck-pX rats) often develop epithelial thymomas that are considered benign since they never invade neighboring organs or metastasize. In this issue, the same group (Tsuji et al, 2 p. 851) describes the malignant transformation of epithelial thymomas induced by heterotopic transplantation of thymuses from newborn lck-pX rats into the subcapsular space of kidneys of thymectomized lck-pX rats. At 3 months after transplantation, tumors histologically similar to the benign thymomas were present in the subcapsular space, indicating that thymomas can also develop at heterotopic sites. At 6 months, however, malignant transformation occurred, attributed to the presence of local tissue factors. In comparison to the benign thymomas, the malignant tumors were highly proliferative, metastatic, and transplantable. In addition, the expression of the pX transgene in the malignant thymomas was significantly reduced, and the expression of critical host genes such as the cyclin-dependent kinase inhibitor p16ink4a/ARF, which was significantly upregulated in the benign thymomas, was undetectable in the malignant forms, most likely due to a homozygous gene deletion. It is therefore worth noting that p16ink4a and ARF are tumor suppressor genes, and abnormalities of these genes are present in a significant number of human malignancies. The findings of Tsuji et al suggest that p16ink4a expression may play a role in thymoma transformation. In benign thymomas with aberrant expressions of the pX gene, the high levels of p16ink4a expression may control tumor growth. Deletion of this gene and alteration of cell cycle regulation may lead to a state of higher malignancy. Furthermore, the results suggest that the transformed tumor cells may not require the expression of pX gene for further growth. The exact process of thymoma transformation in this model system remains unclear. Regardless of the mechanism involved, however, this rat model may become a very useful tool in the study of tumorigenesis of thymomas in vivo.
